¿Qué estás buscando? Escribe el nombre, el título o cualquier palabra clave relacionada con lo que estás buscando y selecciona a qué categoría de contenido pertenece. Buscar Fulltext search Actividades Profesionales Grupos de investigación Noticias - Cualquiera - Year 2019 Referencia Front Aging Neurosci. 2020 Jan 21;11:367. doi: 10.3389/fnagi.2019.00367. eCollection 2019. Tipus publicació Revisión en revista internacional DOI http://dx.doi.org/10.3389/fnagi.2019.00367 Revista Frontiers in Aging Neuroscience Títol Complet Functional Near-Infrared Spectroscopy to Study Cerebral Hemodynamics in Older Adults During Cognitive and Motor Tasks: A Review. Autors Carmina Castellano Tejedor Marco Inzitari Laura Mónica Perez Bazan Luis Ignacio Soto Bargaria Cristina Udina Argilaga Codi 47750 PMID https://pubmed.ncbi.nlm.nih.gov/32038224 Nom Autors Avtzi, Stella; Castellano-Tejedor, Carmina; Durduran, Turgut; Holtzer, Roee; Inzitari, Marco; Perez, Laura-Monica; Rosso, Andrea L; Soto-Bagaria, Luis; Udina, Cristina et al. DOI número 10.3389/fnagi.2019.00367 Year 2019 Referencia J Spine Surg. 2019 Dec;5(4):535-540. doi: 10.21037/jss.2019.11.12. Tipus publicació Artículo en revista internacional DOI http://dx.doi.org/10.21037/jss.2019.11.12 Revista Journal of spine surgery (Hong Kong) Títol Complet The effect of increasing body mass index on the pain and function of patients with adult spinal deformity. Autors Ferran Pellisé Uriquiza Codi 47749 PMID https://pubmed.ncbi.nlm.nih.gov/32043004 Nom Autors Acaroglu, Emre; Alanay, Ahmet; Boissiere, Louis; Bourghli, Anouar; Cawley, Derek Thomas; Fujishiro, Takashi; Gille, Olivier; Hayashi, Kazunori; Kieser, David Christopher; Kleinstueck, Frank et al. DOI número 10.21037/jss.2019.11.12 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.224 Revista ANNALS OF ONCOLOGY Títol Complet Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Codi 47748 PMID https://pubmed.ncbi.nlm.nih.gov/32085233 Nom Autors Abou-Alfa, G; Berman, C; Borbath, I; Cho, T; Clarke, S; Hitre, E; Howland, M; Javle, M; Louvet, C; Macarulla, T et al. DOI número 10.1093/annonc/mdz155.224 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.190 Revista ANNALS OF ONCOLOGY Títol Complet Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Codi 47747 PMID https://pubmed.ncbi.nlm.nih.gov/32085197 Nom Autors Alvarez, R; Aparicio, J; Bosch, C; Camara, J; Capdevila, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernandez-Yague, X et al. DOI número 10.1093/annonc/mdz155.190 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv51-iv52. doi: 10.1093/annonc/mdz155.189. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.189 Revista ANNALS OF ONCOLOGY Títol Complet Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients. Codi 47746 PMID https://pubmed.ncbi.nlm.nih.gov/32085195 Nom Autors Alcaide Garcia, J; Alcaraz Nunes, D; Castanon Lopez, C; de Toro Carmena, M; Diaz Beveridge, R; Encinas Garcia, S; Fernandez Montes, A; Garcia Adrian, S; Garcia Alfonso, P; Garcia Paredes, B et al. DOI número 10.1093/annonc/mdz155.189 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv25. doi: 10.1093/annonc/mdz155.093. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.093 Revista ANNALS OF ONCOLOGY Títol Complet KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Codi 47745 PMID https://pubmed.ncbi.nlm.nih.gov/32085099 Nom Autors Bang, Y; Cao, Z; Chen, X; Chung, H; Fuchs, C; Janjigian, Y; Kang, S; Qin, S; Satoh, T; Shih, C et al. DOI número 10.1093/annonc/mdz155.093 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.004 Revista ANNALS OF ONCOLOGY Títol Complet BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. Codi 47744 PMID https://pubmed.ncbi.nlm.nih.gov/32085058 Nom Autors Anderson, L; Arkenau, H; Christy-Bittel, J; Ciardiello, F; Desai, J; Garcia Alfonso, P; Gollerkeri, A; Grothey, A; Guren, T; Hong, Y et al. DOI número 10.1093/annonc/mdz183.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152-iv153. doi: 10.1093/annonc/mdz183.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.001 Revista ANNALS OF ONCOLOGY Títol Complet Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Codi 47743 PMID https://pubmed.ncbi.nlm.nih.gov/32085055 Nom Autors Bang, Y; Braghiroli, M; Castro Salguero, H; Chao, J; Chung, H; Fuchs, C; Garrido, M; Goekkurt, E; Kang, S; Kher, U et al. DOI número 10.1093/annonc/mdz183.001 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183 Revista ANNALS OF ONCOLOGY Títol Complet Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. Codi 47742 PMID https://pubmed.ncbi.nlm.nih.gov/32085054 Nom Autors Algul, H; Arnold, D; Cui, K; Golan, T; Hall, M; Hammel, P; Hochhauser, D; Kindler, H; Locker, G; Macarulla, T et al. DOI número 10.1093/annonc/mdz183 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.025. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.025 Revista ANNALS OF ONCOLOGY Títol Complet Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Codi 47741 PMID https://pubmed.ncbi.nlm.nih.gov/32085044 Nom Autors Alfonso, P Garcia; Aranda, E; Argiles, G; Benavides, M; Bennouna, J; Cano, T; Ciardiello, F; de Prado, J Vieitez; Falcone, A; Garrote, M Rodriguez et al. DOI número 10.1093/annonc/mdz154.025 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv127. doi: 10.1093/annonc/mdz154.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.004 Revista ANNALS OF ONCOLOGY Títol Complet Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Codi 47740 PMID https://pubmed.ncbi.nlm.nih.gov/32085018 Nom Autors Bernstam, F Meric; Borad, M; Brana, I; Bryce, R; Cleary, J; Cutler, R; Dujka, M; Eli, L; Harding, J; Hyman, D et al. DOI número 10.1093/annonc/mdz154.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154 Revista ANNALS OF ONCOLOGY Títol Complet An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Codi 47739 PMID https://pubmed.ncbi.nlm.nih.gov/32085016 Nom Autors Bekaii-Saab, T; Berlin, J; Biankin, A; Bruchec, Y Le; Dhani, N; Frassineti, G; Goldstein, D; Macarulla, T; Noel, M; O'Reilly, E et al. DOI número 10.1093/annonc/mdz154 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.001 Revista ANNALS OF ONCOLOGY Títol Complet Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Codi 47738 PMID https://pubmed.ncbi.nlm.nih.gov/32085015 Nom Autors Bachet, J; Chang, H; Cole, G Jr; Coussens, L; Fong, L; Hendifar, A; James, D; Lonardi, S; Macarulla, T; Maurel, J et al. DOI número 10.1093/annonc/mdz154.001 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv125. doi: 10.1093/annonc/mdz157.009. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.009 Revista ANNALS OF ONCOLOGY Títol Complet Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. Codi 47737 PMID https://pubmed.ncbi.nlm.nih.gov/32085014 Nom Autors Baumeister, H; Conte, G; Fiedler, W; Garralda, E; Habel, B; Kebenko, M; Klinghammer, K; Matos, I; Ochsenreither, S; Raspagliesi, F et al. DOI número 10.1093/annonc/mdz157.009 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv123. doi: 10.1093/annonc/mdz157.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.004 Revista ANNALS OF ONCOLOGY Títol Complet A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Codi 47736 PMID https://pubmed.ncbi.nlm.nih.gov/32085008 Nom Autors Belanger, B; Boland, P; Dayyani, F; Dean, A; Lieu, C; Macarulla, T; Maxwell, F; Moore, Y; Wainberg, Z; Wang, T et al. DOI número 10.1093/annonc/mdz157.004 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv122-iv123. doi: 10.1093/annonc/mdz157.002. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.002 Revista ANNALS OF ONCOLOGY Títol Complet Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Codi 47735 PMID https://pubmed.ncbi.nlm.nih.gov/32085006 Nom Autors Bernstam, F Meric; Chessex, A Vaslin; Cleary, J; Flaherty, K; Goyal, L; Hu, Y; Hyman, D; Ishii, N; Iyer, G; Kirpicheva, Y et al. DOI número 10.1093/annonc/mdz157.002 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv117. doi: 10.1093/annonc/mdz156.023. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156.023 Revista ANNALS OF ONCOLOGY Títol Complet Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. Codi 47734 PMID https://pubmed.ncbi.nlm.nih.gov/32084991 Nom Autors Argiles, G; Mayer, R; Moreno Vera, S; Ohtsu, A; Sobrero, A; Tabernero, J; Van Cutsem, E; Vidot, L et al. DOI número 10.1093/annonc/mdz156.023 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156 Revista ANNALS OF ONCOLOGY Títol Complet Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Codi 47733 PMID https://pubmed.ncbi.nlm.nih.gov/32084969 Nom Autors Bendell, J; Berlin, J; Chang, H; Diaz, I Ales; Garlipp, B; Goldstein, D; Jeanes, J; Lu, B; Macarulla, T; Milella, M et al. DOI número 10.1093/annonc/mdz156 Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv109. doi: 10.1093/annonc/mdz155.399. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.399 Revista ANNALS OF ONCOLOGY Títol Complet ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Codi 47732 PMID https://pubmed.ncbi.nlm.nih.gov/32084963 Nom Autors Chetaille, E; Groc, M; Grothey, A; Paez, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vedovato, J; Yaeger, R; Yoshino, T et al. DOI número 10.1093/annonc/mdz155.399 Year 2019 Tipus publicació Revisión en revista internacional DOI http://dx.doi.org/10.1007/978-3-030-02278-5_41 Títol Complet Graft Failure Codi 47731 PMID https://pubmed.ncbi.nlm.nih.gov/32091792 Nom Autors Sureda, Anna; Valcarcel, David et al. DOI número 10.1007/978-3-030-02278-5_41 Paginación Primera página « Página anterior ‹ … Página 2131 Página 2132 Página actual 2133 Página 2134 Página 2135 … Siguiente página › Última página »
Year 2019 Referencia Front Aging Neurosci. 2020 Jan 21;11:367. doi: 10.3389/fnagi.2019.00367. eCollection 2019. Tipus publicació Revisión en revista internacional DOI http://dx.doi.org/10.3389/fnagi.2019.00367 Revista Frontiers in Aging Neuroscience Títol Complet Functional Near-Infrared Spectroscopy to Study Cerebral Hemodynamics in Older Adults During Cognitive and Motor Tasks: A Review. Autors Carmina Castellano Tejedor Marco Inzitari Laura Mónica Perez Bazan Luis Ignacio Soto Bargaria Cristina Udina Argilaga Codi 47750 PMID https://pubmed.ncbi.nlm.nih.gov/32038224 Nom Autors Avtzi, Stella; Castellano-Tejedor, Carmina; Durduran, Turgut; Holtzer, Roee; Inzitari, Marco; Perez, Laura-Monica; Rosso, Andrea L; Soto-Bagaria, Luis; Udina, Cristina et al. DOI número 10.3389/fnagi.2019.00367
Year 2019 Referencia J Spine Surg. 2019 Dec;5(4):535-540. doi: 10.21037/jss.2019.11.12. Tipus publicació Artículo en revista internacional DOI http://dx.doi.org/10.21037/jss.2019.11.12 Revista Journal of spine surgery (Hong Kong) Títol Complet The effect of increasing body mass index on the pain and function of patients with adult spinal deformity. Autors Ferran Pellisé Uriquiza Codi 47749 PMID https://pubmed.ncbi.nlm.nih.gov/32043004 Nom Autors Acaroglu, Emre; Alanay, Ahmet; Boissiere, Louis; Bourghli, Anouar; Cawley, Derek Thomas; Fujishiro, Takashi; Gille, Olivier; Hayashi, Kazunori; Kieser, David Christopher; Kleinstueck, Frank et al. DOI número 10.21037/jss.2019.11.12
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv62. doi: 10.1093/annonc/mdz155.224. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.224 Revista ANNALS OF ONCOLOGY Títol Complet Phase 3 multicenter, open-label, randomized study of infigratinib versus gemcitabine plus cisplatin in the first-line treatment of patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF trial. Codi 47748 PMID https://pubmed.ncbi.nlm.nih.gov/32085233 Nom Autors Abou-Alfa, G; Berman, C; Borbath, I; Cho, T; Clarke, S; Hitre, E; Howland, M; Javle, M; Louvet, C; Macarulla, T et al. DOI número 10.1093/annonc/mdz155.224
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv52. doi: 10.1093/annonc/mdz155.190. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.190 Revista ANNALS OF ONCOLOGY Títol Complet Randomized phase II clinical trial to evaluate the efficacy of second-line FOLFIRI-panitumumab in patients with RAS wild-type metastatic colorectal cancer who have received FOLFOX-panitumumab in first-line (BEYOND). Codi 47747 PMID https://pubmed.ncbi.nlm.nih.gov/32085197 Nom Autors Alvarez, R; Aparicio, J; Bosch, C; Camara, J; Capdevila, J; Fernandez-Martos, C; Fernandez-Plana, J; Gallego, J; Gallego, R; Hernandez-Yague, X et al. DOI número 10.1093/annonc/mdz155.190
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv51-iv52. doi: 10.1093/annonc/mdz155.189. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.189 Revista ANNALS OF ONCOLOGY Títol Complet Update of metastatic colorectal cancer metastases resection after FOLFIRI-aflibercept in oxaliplatin-refractory patients. Codi 47746 PMID https://pubmed.ncbi.nlm.nih.gov/32085195 Nom Autors Alcaide Garcia, J; Alcaraz Nunes, D; Castanon Lopez, C; de Toro Carmena, M; Diaz Beveridge, R; Encinas Garcia, S; Fernandez Montes, A; Garcia Adrian, S; Garcia Alfonso, P; Garcia Paredes, B et al. DOI número 10.1093/annonc/mdz155.189
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv25. doi: 10.1093/annonc/mdz155.093. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.093 Revista ANNALS OF ONCOLOGY Títol Complet KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer: a double-blind, randomized, placebo-controlled phase 3 study. Codi 47745 PMID https://pubmed.ncbi.nlm.nih.gov/32085099 Nom Autors Bang, Y; Cao, Z; Chen, X; Chung, H; Fuchs, C; Janjigian, Y; Kang, S; Qin, S; Satoh, T; Shih, C et al. DOI número 10.1093/annonc/mdz155.093
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv154. doi: 10.1093/annonc/mdz183.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.004 Revista ANNALS OF ONCOLOGY Títol Complet BEACON CRC: a randomized, 3-Arm, phase 3 study of encorafenib and cetuximab with or without binimetinib vs. choice of either irinotecan or FOLFIRI plus cetuximab in BRAF V600E-mutant metastatic colorectal cancer. Codi 47744 PMID https://pubmed.ncbi.nlm.nih.gov/32085058 Nom Autors Anderson, L; Arkenau, H; Christy-Bittel, J; Ciardiello, F; Desai, J; Garcia Alfonso, P; Gollerkeri, A; Grothey, A; Guren, T; Hong, Y et al. DOI número 10.1093/annonc/mdz183.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152-iv153. doi: 10.1093/annonc/mdz183.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183.001 Revista ANNALS OF ONCOLOGY Títol Complet Pembrolizumab with or without chemotherapy versus chemotherapy for first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The Phase 3 KEYNOTE-062 Study. Codi 47743 PMID https://pubmed.ncbi.nlm.nih.gov/32085055 Nom Autors Bang, Y; Braghiroli, M; Castro Salguero, H; Chao, J; Chung, H; Fuchs, C; Garrido, M; Goekkurt, E; Kang, S; Kher, U et al. DOI número 10.1093/annonc/mdz183.001
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv152. doi: 10.1093/annonc/mdz183. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz183 Revista ANNALS OF ONCOLOGY Títol Complet Olaparib as maintenance treatment following first-line platinum-based chemotherapy in patients with a germline BRCA mutation and metastatic pancreatic cancer: phase III POLO trial. Codi 47742 PMID https://pubmed.ncbi.nlm.nih.gov/32085054 Nom Autors Algul, H; Arnold, D; Cui, K; Golan, T; Hall, M; Hammel, P; Hochhauser, D; Kindler, H; Locker, G; Macarulla, T et al. DOI número 10.1093/annonc/mdz183
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv135. doi: 10.1093/annonc/mdz154.025. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.025 Revista ANNALS OF ONCOLOGY Títol Complet Results of REARRANGE trial: A randomized phase 2 study comparing different dosing approaches for regorafenib (REG) during the first cycle of treatment in patients (pts) with metastatic colorectal cancer (mCRC). Codi 47741 PMID https://pubmed.ncbi.nlm.nih.gov/32085044 Nom Autors Alfonso, P Garcia; Aranda, E; Argiles, G; Benavides, M; Bennouna, J; Cano, T; Ciardiello, F; de Prado, J Vieitez; Falcone, A; Garrote, M Rodriguez et al. DOI número 10.1093/annonc/mdz154.025
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv127. doi: 10.1093/annonc/mdz154.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.004 Revista ANNALS OF ONCOLOGY Títol Complet Treating HER2-mutant advanced biliary tract cancer with neratinib: benefits of HER2-directed targeted therapy in the phase 2 SUMMIT 'basket' trial. Codi 47740 PMID https://pubmed.ncbi.nlm.nih.gov/32085018 Nom Autors Bernstam, F Meric; Borad, M; Brana, I; Bryce, R; Cleary, J; Cutler, R; Dujka, M; Eli, L; Harding, J; Hyman, D et al. DOI número 10.1093/annonc/mdz154.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154 Revista ANNALS OF ONCOLOGY Títol Complet An international, randomized, open-label, phase III trial of adjuvant nab-paclitaxel plus gemcitabine vs gemcitabine alone for surgically resected pancreatic adenocarcinoma (APACT): primary analysis and quality of life outcomes. Codi 47739 PMID https://pubmed.ncbi.nlm.nih.gov/32085016 Nom Autors Bekaii-Saab, T; Berlin, J; Biankin, A; Bruchec, Y Le; Dhani, N; Frassineti, G; Goldstein, D; Macarulla, T; Noel, M; O'Reilly, E et al. DOI número 10.1093/annonc/mdz154
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv126. doi: 10.1093/annonc/mdz154.001. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz154.001 Revista ANNALS OF ONCOLOGY Títol Complet Ibrutinib in combination with nab-paclitaxel and gemcitabine as first-line treatment for patients with metastatic pancreatic adenocarcinoma: results from the phase 3 RESOLVE study. Codi 47738 PMID https://pubmed.ncbi.nlm.nih.gov/32085015 Nom Autors Bachet, J; Chang, H; Cole, G Jr; Coussens, L; Fong, L; Hendifar, A; James, D; Lonardi, S; Macarulla, T; Maurel, J et al. DOI número 10.1093/annonc/mdz154.001
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv125. doi: 10.1093/annonc/mdz157.009. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.009 Revista ANNALS OF ONCOLOGY Títol Complet Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors. Codi 47737 PMID https://pubmed.ncbi.nlm.nih.gov/32085014 Nom Autors Baumeister, H; Conte, G; Fiedler, W; Garralda, E; Habel, B; Kebenko, M; Klinghammer, K; Matos, I; Ochsenreither, S; Raspagliesi, F et al. DOI número 10.1093/annonc/mdz157.009
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv123. doi: 10.1093/annonc/mdz157.004. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.004 Revista ANNALS OF ONCOLOGY Títol Complet A phase 1/2, open-label, dose-expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer. Codi 47736 PMID https://pubmed.ncbi.nlm.nih.gov/32085008 Nom Autors Belanger, B; Boland, P; Dayyani, F; Dean, A; Lieu, C; Macarulla, T; Maxwell, F; Moore, Y; Wainberg, Z; Wang, T et al. DOI número 10.1093/annonc/mdz157.004
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv122-iv123. doi: 10.1093/annonc/mdz157.002. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz157.002 Revista ANNALS OF ONCOLOGY Títol Complet Debio 1347 in patients with gastrointestinal cancers harboring an FGFR gene fusion: preliminary results. Codi 47735 PMID https://pubmed.ncbi.nlm.nih.gov/32085006 Nom Autors Bernstam, F Meric; Chessex, A Vaslin; Cleary, J; Flaherty, K; Goyal, L; Hu, Y; Hyman, D; Ishii, N; Iyer, G; Kirpicheva, Y et al. DOI número 10.1093/annonc/mdz157.002
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv117. doi: 10.1093/annonc/mdz156.023. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156.023 Revista ANNALS OF ONCOLOGY Títol Complet Exploratory analysis of the effect of FTD/TPI in mCRC patients treated in RECOURSE by different prognostic factors: impact on ECOG PS. Codi 47734 PMID https://pubmed.ncbi.nlm.nih.gov/32084991 Nom Autors Argiles, G; Mayer, R; Moreno Vera, S; Ohtsu, A; Sobrero, A; Tabernero, J; Van Cutsem, E; Vidot, L et al. DOI número 10.1093/annonc/mdz156.023
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv110. doi: 10.1093/annonc/mdz156. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz156 Revista ANNALS OF ONCOLOGY Títol Complet Analysis of patient screening in the phase III, international, randomized, open-label APACT trial. Codi 47733 PMID https://pubmed.ncbi.nlm.nih.gov/32084969 Nom Autors Bendell, J; Berlin, J; Chang, H; Diaz, I Ales; Garlipp, B; Goldstein, D; Jeanes, J; Lu, B; Macarulla, T; Milella, M et al. DOI número 10.1093/annonc/mdz156
Year 2019 Referencia Ann Oncol. 2019 Jul;30 Suppl 4:iv109. doi: 10.1093/annonc/mdz155.399. Epub 2019 Dec 4. Tipus publicació Carta o abstract DOI http://dx.doi.org/10.1093/annonc/mdz155.399 Revista ANNALS OF ONCOLOGY Títol Complet ANCHOR CRC: a phase 2, open-label, single arm, multicenter study of encorafenib (ENCO), binimetinib (BINI), plus cetuximab (CETUX) in patients with previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). Codi 47732 PMID https://pubmed.ncbi.nlm.nih.gov/32084963 Nom Autors Chetaille, E; Groc, M; Grothey, A; Paez, D; Tabernero, J; Taieb, J; Van Cutsem, E; Vedovato, J; Yaeger, R; Yoshino, T et al. DOI número 10.1093/annonc/mdz155.399
Year 2019 Tipus publicació Revisión en revista internacional DOI http://dx.doi.org/10.1007/978-3-030-02278-5_41 Títol Complet Graft Failure Codi 47731 PMID https://pubmed.ncbi.nlm.nih.gov/32091792 Nom Autors Sureda, Anna; Valcarcel, David et al. DOI número 10.1007/978-3-030-02278-5_41
